Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between -135 million yuan and -90 million yuan[3]. - The estimated operating revenue for 2025 is projected to be between 210 million yuan and 260 million yuan, with the revenue after excluding non-core business income expected to be between 207 million yuan and 257 million yuan, both below 300 million yuan[3][6]. - The previous year's (2024) operating revenue was approximately 329.5 million yuan, indicating a significant decline in revenue for 2025[7]. - The decrease in revenue is attributed to the disposal of a subsidiary, which reduced pharmaceutical segment income by about 30 million yuan, and a decline in clothing business revenue compared to the previous year[8]. - The company recorded an increase in impairment losses of approximately 40 million yuan for inventory, fixed assets, and receivables compared to the previous year[8]. - The basic earnings per share for the previous year (2024) was -0.19 yuan per share[7]. Earnings Forecast and Risks - The company has not identified any significant uncertainties affecting the accuracy of this earnings forecast[9]. - The earnings forecast is based on preliminary calculations by the finance department and has not yet been audited[4][9]. - If the audited results show a net profit or total profit below zero and operating revenue below 300 million yuan, the company's stock will face delisting risk warnings according to the Shanghai Stock Exchange regulations[4][9]. - The company will provide detailed data in its 2025 annual report, which is expected to be released later[4].
美尔雅(600107) - 2025 Q4 - 年度业绩预告